Navigation Links
InterMune Announces Fourth Quarter and Full Year 2007 Financial Results and Provides 2008 Guidance
Date:2/7/2008

sting supply agreement with Boehringer Ingelheim Austria for the commercial and clinical supply of Actimmune.

Fourth Quarter and Recent Business Highlights

-- Pirfenidone: On November 26, InterMune announced that it had entered

into agreements with Marnac, Inc. and with co-licensor KDL GmbH that

will eliminate future royalty and milestone payment obligations for

pirfenidone related to the 2002 license agreement. The principal terms

of the new agreements were:

-- InterMune made total acquisition payments to the companies of $13.7

million. Of this total, a $7.5 million expense recorded in the

third quarter of 2007 relating to the 2002 license agreement was

applied to the acquisition payments for the new agreements. The

$6.2 million balance of the acquisition payments for the new

agreements was recorded in the fourth quarter of 2007.

-- Contingent acquisition payments associated with the new agreements

of up to an additional $53.5 million would be made by InterMune

only if positive Phase 3 data and registration in the United States

and European Union are achieved.

-- In addition, InterMune acquired exclusive worldwide rights from

Marnac to certain additional intellectual property for pirfenidone

that was not licensed under the 2002 licensing agreement, including

patents relating to the TNF-alpha activities of the compound.

-- ITMN-191: On January 7, 2008, InterMune reported the progress of its

Phase 1b multiple-ascending-dose (MAD) clinical trial evaluating

ITMN-191 (R7227) as monotherapy in patients with chronic hepatitis C

virus (HCV) infection. InterMune reported that:

-- It had completed the first two dosage cohorts in the study, with

total daily doses of up to 300mg, and that
'/>"/>

SOURCE InterMune, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. InterMune to Present at Thomas Weisel and Bear Stearns Healthcare Conferences
2. InterMune Announces Proposed Public Offering of Common Stock
3. InterMune Announces Pricing of $68 Million Public Offering of Common Stock
4. InterMune Announces Closing of Public Offering of Common Stock
5. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
6. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
7. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
8. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
9. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
10. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... -- Research and Markets  has announced the ... report to their offering. ... Metabonomics is the scientific study of chemical processes ... technique that is being widely used in biology, ... molecules that are present in blood, urine, and ...
(Date:7/25/2014)... San Diego, CA (PRWEB) July 25, 2014 ... “Paws” For Your Pet with Lorry Young will be ... DVM, to talk about stem cell therapy in pets. ... discuss the benefits of stem cell therapy for pets suffering ... developments moving the Regenerative Veterinary Medicine industry forward. , Young ...
(Date:7/25/2014)... 2014 Lawrence Livermore scientists Charles Westbrook ... list of " The World's Most Influential Scientific Minds ... 3,000 researchers who were identified by analyzing citation data ... published the highest-impact work (2002-2012 and 2012-2013). The two ... combustion modeling . , "This recognition is a great ...
(Date:7/25/2014)... 2014 /PRNewswire-iReach/ -- Xybion Corporation, the leading provider ... operating in highly regulated industries, announced today that ... User Group Conference, Xybion International Exchange, on October ... at the Sheraton Society Hill Hotel.  ... This year,s conference theme is Compliance ...
Breaking Biology Technology:Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 2Robert J. Harman, DVM, Founder and CEO of Vet-Stem, Inc. to Join New York Radio Host Lorry Young in Upcoming Episode of A “Paws” For Your Pet 3Scientists Burst onto Influential List for Combustion Research 2Scientists Burst onto Influential List for Combustion Research 3Scientists Burst onto Influential List for Combustion Research 4Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3
... /PRNewswire-Asia-FirstCall/ -- China Sky One Medical,Inc. ("China Sky ... CSKI ), a leading,fully integrated pharmaceutical company producing ... today announced that the Company,s,Chief Financial Officer, Mr. ... at the upcoming Roth 21st Annual OC Growth ...
... COTTAGE, N.Y., Feb. 5 XTL,Biopharmaceuticals Ltd. (Nasdaq: ... February 3, 2009 the Company received a letter from ... outstanding ordinary shares requesting the,convening of an extraordinary shareholders, ... address and approve the following matters: , ...
... Va., Feb. 5, 2009 AMERIGROUP Chairman and Chief ... on legislation expanding the State Children,s Health Insurance Program ... of America,s children deserve a healthy start in life, ... see a family doctor and get the healthcare they ...
Cached Biology Technology:China Sky One Medical, Inc. CFO to Present at Roth Conference 2China Sky One Medical, Inc. CFO to Present at Roth Conference 3Corrected: XTL Biopharmaceuticals to Convene Extraordinary Shareholders' Meetings after Receipt of Shareholder Letter 2AMERIGROUP Praises Expansion of State Children's Health Insurance Program (SCHIP) 2
(Date:7/25/2014)... For the first time, Spanish researchers have detected an ... coli cells are introduced into a droplet of ... the sodium chloride crystallisation to create biomineralogical biosaline 3D ... rehydrating the material, bacteria are revived. The discovery was ... made the cover of the Astrobiology journal ...
(Date:7/24/2014)... Scientists at The New York Stem Cell Foundation ... creating a viable cell replacement therapy for multiple ... For the first time, NYSCF scientists generated induced ... of patients with primary progressive multiple sclerosis and ... these stem cells into becoming oligodendrocytes, the myelin-forming ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
Breaking Biology News(10 mins):Bacteria manipulate salt to build shelters to hibernate 2NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
... for the body to make estrogen, are no longer a ... Ghosh lab at the Hauptman-Woodward Medical Research Institute (HWI) in ... three-dimensional structure of aromatase is the first time that scientists ... In fact, the Ghosh lab has determined the ...
... shows the resistance of the avian flu virus to a ... selection, with researchers documenting the trend in more than 30 ... Influenza A subtype dubbed H5N1, is evolving a resistance to ... two classes of antiviral drugs used to prevent and treat ...
... drug therapy called fenobam has shown promising initial results and ... with Fragile X syndrome (FXS). Findings of the open ... and the University of California, Davis, Medical Center are to ... Journal of Medical Genetics . Results of ...
Cached Biology News:HWI scientist first in world to unravel structure of key breast cancer target enzyme 2HWI scientist first in world to unravel structure of key breast cancer target enzyme 3Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 2Avian flu becoming more resistant to antiviral drugs, says University of Colorado study 3Promising new drug being evaluated as possible treatment option for fragile X syndrome 2
384 Well PCR Plate Carrier for Thermo-Sealer...
... Collection of Cell Cultures (ECACC) has been ... academia and government institutes for over seven ... designed to introduce candidates to cell culture ... on more specialist areas such as planning ...
...
... used to perform runs with and ... Experion automated electrophoresis system. The software ... gel views and summarizes size, concentration, ... table. This software is for use ...
Biology Products: